Mylan launches first Targretin generic

PITTSBURGH — Mylan announced Thursday that it had launched its generic version of Valeant’s Targretin (bexarotene) 75-mg capsules. The medication, which IMS Health says generated $155.5 million in sales in the 12 months ending March 31, is intended to treat patients with cutaneous t-cell lymphoma and who are refractory to at least one prior systemic therapy.

“Mylan's launch of the first and only generic Targretin is another example of our commitment to expand access to high quality, more affordable medicines,” Mylan CEO Heather Bresch said. “The launch also strengthens Mylan's growing oncology franchise of more than 30 approved oncology treatments, and associated supportive care and diagnostic products in the U.S. We look forward to continue meeting patient, payor and provider needs in this space.”

Mylan currently has 270 ANDAs waiting for FDA approval, 47 of which are firt-to-file opportunities.